HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

diazoluminolmelanin

synthetic luminescent biopolymer
Also Known As:
DALM
Networked: 47 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Fogt, F: 4 articles (06/2001 - 03/2000)
2. Urbanski, S J: 3 articles (06/2001 - 03/2000)
3. Noffsinger, A E: 3 articles (06/2001 - 03/2000)
4. Zimmerman, R L: 3 articles (06/2001 - 03/2000)
5. Farraye, Francis A: 2 articles (05/2013 - 07/2004)
6. Odze, Robert D: 2 articles (05/2013 - 07/2004)
7. Esposito, Dario: 2 articles (01/2012 - 02/2011)
8. Siano, Maria: 2 articles (01/2012 - 02/2011)
9. Staibano, Stefania: 2 articles (01/2012 - 02/2011)
10. Poremba, C: 2 articles (06/2001 - 06/2001)

Related Diseases

1. Adenoma (Adenomas)
2. Polyps
12/01/2008 - "The problems that arise are: (1) the surveillance program is different in each guideline; (2) the biopsy number that the guidelines propose for surveillance is too large to observe, and there is no adequate evidence of benefit from this number; (3) direct evidence to prove the efficacy of the present surveillance methods is not shown; (4) significant variability is thought to exist between diagnosticians in the diagnosis of low-grade dysplasia (LGD) and indefinite dysplasia (IND); (5) a consensus has not been reached about the management of flat LGD; (6) there is disagreement about the definition of dysplasia-associated lesions (DALM), and there are cases where the differentiation of DALM, adenoma-like mass (ALM)/adenoma-like dysplasia (ALD), sporadic adenoma and even inflammatory polyps is difficult. "
01/01/2013 - "Large serrated polyp with KRAS mutation in inflammatory bowel disease: a "nondysplastic dysplasia-associated lesion or mass (DALM)"?"
07/01/2004 - "There was no significant difference in the prevalence of polyp formation on follow-up evaluation between UC patients with an adenoma-like DALM (62.5%) and UC patients with a sporadic adenoma (50%), or between either of these 2 UC patient subgroups and the non-UC sporadic adenoma patient group (49%; P > 0.05). "
06/01/2001 - "In adenomas, KI-67 was expressed preponderantly at the luminal aspect of the polyp, whereas its expression was diffuse in DALM. "
06/01/2001 - "Dysplastic polyps of patients with ulcerative colitis (UC) may represent dysplasia-associated lesions or masses (DALM) with a high associated cancer risk, or, alternatively, may represent sporadic adenomas. "
3. Adenocarcinoma
4. Ulcerative Colitis
5. Neoplasms (Cancer)

Related Drugs and Biologics

1. Phenobarbital (Luminal)
2. Genetic Markers (Genetic Marker)
3. Carrier Proteins (Binding Protein)
4. N-methylsuccinimide

Related Therapies and Procedures

1. Colectomy
2. Lasers (Laser)